SWITCH: Apixaban vs. Vitamin K bei HM3
Die SWITCH-Studie: Eine randomisierte kontrollierte Studie zu Apixaban versus Vitamin-K-Antagonisten bei Patienten mit HeartMate-3-Linksventrikulären Unterstützungssystemen
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Heart failure is a global epidemic, and Left Ventricular Assist Devices (LVADs) - particularly the HeartMate 3 (HM3) - are increasingly used due to their survival benefit over medical therapy. Despite advances, hemocompatibility-related adverse events (HRAEs) like thrombosis and bleeding remain significant causes of morbidity and mortality.
Direct Oral Anticoagulants (DOACs) have shown superiority over warfarin in heart failure patients, with lower rates of embolic and intracranial bleeding. Reduced-dose DOACs also appear to reduce major bleeding without increasing thrombotic risk. However, data on their use in LVAD patients is limited, consisting mainly of case reports, small series, retrospective analyses, and a few small randomized clinical trials.
Some reports suggest apixaban may reduce bleeding in high-risk LVAD patients, though cases of pump thrombosis and stroke have occurred. Early studies comparing DOACs to warfarin in patients with HeartMate II (HMII), HeartWare™ HVAD™ System, and The Abbott HeartMate 3 (HM3) show no significant differences in outcomes, with a trend toward less bleeding with apixaban. Two small randomized clinical trials in HM3 patients (The DOAC LVAD Study and The DOT-HM3 Study) found similar results.
This prospective, randomized, controlled, non-inferiority trial will evaluate the safety and efficacy of apixaban versus vitamin K antagonists in HM3 patients more than 3 months post-implant.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Ilan Richter, MD
- Telefonnummer: 3322098345
- E-Mail: ir2498@cumc.columbia.edu
Studienorte
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Rekrutierung
- Columbia University Irving Medical Center
-
Kontakt:
- Ilan Richter, MD
- Telefonnummer: 212-305-7600
- E-Mail: ir2498@cumc.columbia.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participants will have HeartMate3 LVAD implanted > 3 months before enrollment
- ≥ 18 years old
- Treated with WARFARIN SODIUM
- Participant must provide written informed consent prior to any clinical investigation related procedure
- In female participants of childbearing capability, not currently pregnant and on appropriate contraception
Exclusion Criteria:
- Participation in any other clinical investigation(s) involving a Mechanical Circulatory Support (MCS) device, or interventional investigation(s) likely to confound study results or affect study outcome
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
- Known allergy to Apixaban
- Bridge to transplant
- Severe renal dysfunction Estimated Glomerular Filtration Rate (eGFR) <20
- History of major bleeding event with subsequent reduction of INR goal to < 1.8
- Apixaban dose reduction criteria (Age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL)
- Aortic root thrombus
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Warfarin
Participants will take warfarin, dose titrated for an INR >= 1.8 |
Warfarin dose titrated for an International Normalized Ratio (INR) >= 1.8
Andere Namen:
|
|
Experimental: Apixaban
Participants wil take apixaban 5 mg bid |
Apixaban 5 mg bid (twice a day)
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Survival free of major hemocompatibility related adverse event
Zeitfenster: 12 months
|
Major Hemocompatibility Related Adverse Event: Stroke, Pump Thrombosis, major non surgical Bleeding (moderate or severe), Arterial Peripheral Thromboembolism. Rates will be compared between study groups. |
12 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Non-surgical Major Hemorrhagic Events
Zeitfenster: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Non-surgical Major Thrombotic Events
Zeitfenster: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Survival
Zeitfenster: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Stroke Rates
Zeitfenster: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Pump Thrombosis Rates
Zeitfenster: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Bleeding Rates
Zeitfenster: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Rates of listing for Heart Transplant
Zeitfenster: 12 months
|
Rates will be compared between study groups. |
12 months
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Apixaban-Spiegel bei Patienten mit unerwünschten Ereignissen
Zeitfenster: 12 Monate
|
12 Monate
|
|
|
Patient functional status
Zeitfenster: 12 months
|
Association between anticoagulant regimen and New York Heart Association (NYHA) Functional Classification (FC) will be compared between groups. Scores range I through IV, with higher scores indicating worse outcome. |
12 months
|
|
Patient QOL
Zeitfenster: 12 months
|
Kansas City Cardiomyopathy Questionnaire (KCCQ) 12 scores will be compared between groups. Scores range 1-100, with higher scores indicating better health status. |
12 months
|
|
LVAD device speed
Zeitfenster: 12 months
|
LVAD speed (mean, SD) of LVAD will be compared between study groups. Speed ranges 4500-6000 RPM. |
12 months
|
|
LVAD device flow
Zeitfenster: 12 months
|
LVAD flow (mean, SD) of LVAD will be compared between study groups. Flow ranges 3-6 L/min. |
12 months
|
|
LVAD device pulsatility index
Zeitfenster: 12 months
|
LVAD pulsatility index (PI) will be compared between study groups. PI ranges 1-4 (no units). |
12 months
|
|
LVAD device power
Zeitfenster: 12 months
|
LVAD power (mean, SD) will be compared between study groups. Power ranges 3-7 W. |
12 months
|
|
Right atrial pressure
Zeitfenster: 12 months
|
Right atrial (RA) pressure (mean, SD) will be compared between study groups. RA ranges 0-20 mmHg. |
12 months
|
|
Right ventricular systolic pressure
Zeitfenster: 12 months
|
Right ventricular (RV) systolic pressure (mean, SD) will be compared between study groups. RV systolic pressure ranges 0-100 mmHg. |
12 months
|
|
Right ventricular diastolic pressure
Zeitfenster: 12 months
|
Right ventricular (RV) diastolic pressure (mean, SD) will be compared between study groups. RV diastolic pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary artery systolic pressure
Zeitfenster: 12 months
|
Pulmonary artery (PA) systolic pressure (mean, SD) will be compared between study groups. PA systolic pressure ranges 0-100 mmHg. |
12 months
|
|
Pulmonary artery diastolic pressure
Zeitfenster: 12 months
|
Pulmonary artery (PA) diastolic pressure (mean, SD) will be compared between study groups. PA diastolic pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary artery mean pressure
Zeitfenster: 12 months
|
Pulmonary artery (PA) mean pressure (mean, SD) will be compared between study groups. PA mean pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary capillary wedge pressure
Zeitfenster: 12 months
|
Pulmonary capillary wedge pressure (PCWP, mean, SD) will be compared between study groups. PCWP ranges 0-50 mmHg. |
12 months
|
|
Cardiac output
Zeitfenster: 12 months
|
Cardiac output (CO, mean, SD) will be compared between study groups. CO ranges 3-10 L/min. |
12 months
|
|
Invasive hemodynamics
Zeitfenster: 12 months
|
Cardiac index (CI, mean, SD) will be compared between study groups. CI ranges 2.5-4 L/min/m^2. |
12 months
|
|
Drive line infection rates
Zeitfenster: 12 months
|
Rate of drive line infections will be compared between study groups. |
12 months
|
|
VAD coordinator time
Zeitfenster: 12 months
|
Means will be compared between study groups. |
12 months
|
|
Laboratory monitoring
Zeitfenster: 12 months
|
A quantitative comparison of performed laboratory tests to monitor anticoagulation between groups (counts) |
12 months
|
|
Days hospitalized
Zeitfenster: 12 months
|
Means will be compared between study groups. |
12 months
|
|
Caregiver burden
Zeitfenster: 12 months
|
Self assessed caregiver burden will be collected using the validated The Oberst Caregiving Burden Scale (OCBS), and compared between study groups. Scores range 15-75, with higher scores indicating higher levels of caregiving burden (more time spent or greater difficulty). |
12 months
|
|
Time in therapeutic range in the warfarin sodium group
Zeitfenster: 12 months
|
Means, as well as rates above 70%, will be compared between study groups. |
12 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Nir Uriel, MD, New York Presbyterian / Columbia University Medical Center
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Netuka I, Tucanova Z, Ivak P, Gregor S, Kolesar DM, Marek T, Melenovsky V, Binova J, Dorazilova Z, Hegarova M, Podolec M, Riha H, Connors JM, Mehra MR. A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study. Circulation. 2024 Aug 6;150(6):509-511. doi: 10.1161/CIRCULATIONAHA.124.069726. Epub 2024 Apr 9. No abstract available.
- Shah P, Looby M, Dimond M, Bagchi P, Shah B, Isseh I, Rollins AT, Abdul-Aziz AA, Kennedy J, Tang DG, Klein KM, Casselman S, Vermeulen C, Sheaffer W, Snipes M, Sinha SS, O'Connor CM. Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices: The DOAC LVAD Study. JACC Heart Fail. 2024 Sep;12(9):1540-1549. doi: 10.1016/j.jchf.2024.04.013. Epub 2024 May 7.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Zerebrovaskuläre Erkrankungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Pathologische Prozesse
- Herzkrankheiten
- Embolie und Thrombose
- Pathologische Zustände, Anzeichen und Symptome
- Streicheln
- Herzfehler
- Thrombose
- Blutung
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Pyraner
- Cumarine
- Benzopyrans
- 4-Hydroxycoumarine
- Warfarin
- Apixaban
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- AAAV9532
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .